Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus.
Jean-Michel Liet, Cécile Boscher, Christèle Gras-Leguen...
https://pubmed.ncbi.nlm.nih.gov/11953739/Actively Recruiting
Led by University of California, Davis · Updated on 2026-08-18
30
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating dopamine and norepinephrine as first-line vasoactive treatments for term and late preterm newborns with pulmonary hypertension combined with hypoxemic respiratory failure and low blood pressure. This pilot randomized clinical trial aims to compare short-term effects of these treatments on heart and lung function. Pulmonary hypertension causes high blood vessel resistance in the lungs, leading to oxygen problems and risks for newborns. Dopamine is commonly used but may increase lung resistance, while norepinephrine might raise systemic blood pressure with less impact on the lungs. The study involves term and late preterm infants showing lung hypertension and low blood pressure despite receiving fluids. Participants are randomly assigned by time periods to receive either dopamine or norepinephrine as their first vasopressor. Dopamine starts at 5 mcgkgmin, increasing up to 20 mcgkgmin, while norepinephrine starts at 0.02 mcgkgmin, increasing up to 1 mcgkgmin, both adjusted to reach blood pressure targets appropriate for the infants age. Medication use follows standard clinical protocols, and informed consent is obtained for research procedures including repeated heart ultrasound scans. During the study, infants receive serial heart ultrasounds and oxygen measurements to assess blood pressure ratios, heart output, and oxygen levels within 30 hours of starting treatment. Researchers also monitor use of inhaled nitric oxide, need for additional medications, and heart function markers. The trial is conducted at a single center, with study completion expected in June 2027. This research helps understand how these medications affect newborn heart and lung health in pulmonary hypertension with low blood pressure.
CONDITIONS
Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
S
Solomon P Tatagiri, MBBS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Davis
Lead Sponsor
Children's Miracle Network
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dopamine (trial arm) | Norepinephrine (trial arm) |
|---|---|---|
| What it is | An infusion of dopamine starting at 5 mcg/kg/min, titrated to target mean arterial pressure, maximum 20 mcg/kg/min, administered as first‑line vasopressor in hypotensive neonates with PPHN. | An infusion of norepinephrine starting at 0.02 mcg/kg/min, titrated to target mean arterial pressure, maximum 1 mcg/kg/min, administered as first‑line vasopressor in hypotensive neonates with PPHN. |
| Role in the trial | First‑line vasopressor evaluated in randomized arm. | First‑line vasopressor comparator in randomized arm. |
| Primary use in this study | To increase systemic arterial pressure in neonates with pulmonary hypertension and systemic hypotension. | To increase systemic arterial pressure in neonates with pulmonary hypertension and systemic hypotension. |
| How it is given | Continuous intravenous infusion titrated by body weight to maintain blood pressure. | Continuous intravenous infusion titrated by body weight to maintain blood pressure. |
| Evidence status | Widespread clinical use to raise blood pressure in neonatal hypotension, though physiologic effects on pulmonary vascular resistance may be unfavorable. | Animal and observational data suggest norepinephrine may raise systemic pressure with less increase in pulmonary vascular resistance, but prospective efficacy data are lacking. |
| Important risks | May increase pulmonary vascular resistance and worsen oxygenation in PPHN based on physiologic observations. | Potential for systemic vasoconstriction and limited data in this specific neonatal population, risks not fully characterized. |
| Important limitations | Physiologic effects on pulmonary circulation may be detrimental in PPHN; lacks prospective comparative data in this population. | No prospective trial data available in neonates with PPHN until this study; observational or animal data only. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Within 30 hours of vasopressor initiation
Participants receive either dopamine or norepinephrine as their first-line medication to support blood pressure. Dosing is adjusted to meet blood pressure targets based on gestational age.
Continuous infusion with clinical monitoring
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jean-Michel Liet, Cécile Boscher, Christèle Gras-Leguen...
https://pubmed.ncbi.nlm.nih.gov/11953739/Pierre Tourneux, Thameur Rakza, Antoine Bouissou...
https://pubmed.ncbi.nlm.nih.gov/18534241/Robin H Steinhorn
https://pubmed.ncbi.nlm.nih.gov/20216169/Amy L Lesneski, Payam Vali, Morgan E Hardie...
https://pubmed.ncbi.nlm.nih.gov/34356574/Willem P de Boode, Yogen Singh, Samir Gupta...
https://pubmed.ncbi.nlm.nih.gov/27384404/Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/22954275/Patrick J McNamara, Regan E Giesinger, Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/35314154/Patrick J McNamara, Amish Jain, Afif El-Khuffash...
https://pubmed.ncbi.nlm.nih.gov/38309835/Sachin Shah, Saleha Dhalait, Anurag Fursule...
https://pubmed.ncbi.nlm.nih.gov/36302521/P Y Cheung, K J Barrington
https://pubmed.ncbi.nlm.nih.gov/11353933/University of California, Davis
Lead Sponsor
Children's Miracle Network
Collaborating Sponsor